Pioneer Institute study finds IRA discourages non-opioid drug innovation
A study from a US-based public policy research firm has highlighted that the US Inflation Reduction Act (IRA) is likely…
26 Apr 2024
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead therapy, CVN424. The financiers included multiple US-based venture capital firms…
26 Apr 2024
Merck’s net income for Q1 2024 increases by 69% to $4.76bn
Merck & Co Inc (MSD) has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in the first quarter (Q1) of 2024, a 69% rise from $2.82bn…
26 Apr 2024
Multiply Labs and GenScript partner on cell isolation automation
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in cell therapy manufacturing. This collaboration introduces the first fully automated…
26 Apr 2024
Regeneron and Mammoth team up to develop gene editing therapies
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies. This partnership aims to research, develop, and commercialise treatments…
26 Apr 2024
AstraZeneca posts $2.18bn profit after tax in Q1 2024
AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn reported in the same period last year. This growth has…
25 Apr 2024
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Senator Bernie Sanders has targeted the high drug prices of Novo Nordisk’s Ozempic and Wegovy, revealing that the Senate Committee on Health, Education, Labor, and Pensions (HELP) is investigating the…